Vitrolife

Vitrolife Current Assets

The Current Assets of Vitrolife (VITR.ST) as of Nov 9, 2026 is 2.14 B SEK. In the previous year, Current Assets was 2.32 B SEK — a change of -7.96% (lower).

Current Assets

2.14 BSEK

YoY

-7.96%

Last updated:

Current Assets of Vitrolife is 2025 2.14 B SEK. Current Assets of Vitrolife was 2024 2.32 B SEK. It decreases by -7.96% lower compared to the previous year.

The Vitrolife Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
858.81 M SEK
Jan 1, 2019
1.15 B SEK
Jan 1, 2020
1.42 B SEK
Jan 1, 2021
1.41 B SEK
Jan 1, 2022
1.57 B SEK
Jan 1, 2023
1.99 B SEK
Jan 1, 2024
2.32 B SEK
Jan 1, 2025
2.14 B SEK
The Vitrolife Current Assets history
YEARCurrent AssetsYoY
2.14 BSEK-7.96%
2.32 BSEK+16.61%
1.99 BSEK+26.78%
1.57 BSEK+11.76%
1.41 BSEK-1.20%
1.42 BSEK+24.17%
1.15 BSEK+33.52%
858.81 MSEK+20.07%
715.28 MSEK+47.83%
483.85 MSEK+54.18%
313.83 MSEK-16.93%
377.78 MSEK+102.94%
186.15 MSEK+30.31%
142.86 MSEK-6.26%
152.39 MSEK+15.86%
131.53 MSEK+27.72%
102.98 MSEK-2.11%
105.21 MSEK+17.28%
89.71 MSEK+19.45%
75.10 MSEK-18.27%
91.89 MSEK+10.66%
83.04 MSEK+66.54%
49.86 MSEK-51.42%
102.63 MSEK+84.65%
55.58 MSEK+28.10%
43.39 MSEK+29.52%
33.50 MSEK-4.29%
35.00 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

Current Assets of Vitrolife is 2.14 B SEK in 2025.

Current Assets of Vitrolife changed from 2.32 B SEK to 2.14 B SEK, representing a -7.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Vitrolife since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Vitrolife historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vitrolife

All Key Metrics — Vitrolife